Forensic Analysis · Industrials / Manufacturing / Defense · as of Aug 11, 2026

Bruker Corp (BRKR)

A forensic read on Bruker Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Safe

Financial health

4.7

Distress distance

Clean

Earnings quality

Forensic signals

-75.4

P / E (ttm)

-0.4%

ROE

$8.6B

Market cap

0.39%

Dividend yield

2.1%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Bruker Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 4.7, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

0.9%

FY2025

Return on invested capital. Return on invested capital is 0.9% in the latest fiscal year and slipping from 15% — well below its ~9% cost of capital, so reinvested dollars may be destroying value, not building it.

+0.5%/yr

FY2022–FY2025

Share count. Diluted share count changed +2% over the last 3 years to FY2025 (+0.5%/yr). Roughly flat — buybacks ($10M) are about offsetting stock comp ($20M), not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.

$109M

FY2019–FY2025

Goodwill impairments. Took $109M of goodwill writedowns across 5 years (FY2021 ($3M), FY2022 ($3M), FY2025 ($96M)) — about 7% of net income over the span. Writedowns mean past acquisitions underperformed what was paid for them.

-26%

FY2024→FY2025

Dividend — cut. The payout was CUT ~26% in FY2025 (from FY2024). It still returns some cash, but it is NOT the dependable, rising dividend an unbroken streak implies.

Key fundamentals

Latest Revenue$3.44B

Revenue Growth YoY+2.1%

Revenue CAGR (3yr)+10.7%

Net Margin-0.3%

Free Cash Flow$43.3M

Return on Equity-0.4%

Debt / Equity0.76x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Bruker Corp's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.